|
|
Our comprehensive AAV analytical package not only offers insights into viral genome titer but also provides valuable information on its integrity and identity. This cost-effective approach, akin to the setup of traditional 1D or 2D dPCR, holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.
|
|
|
|
Lonza’s AAV transient transfection platform consistently delivers industry leading AAV titers, high full/empty capsid ratio, and overall yield. Lonza’s proprietary suspension HEK293 cell line and plasmids, optimized manufacturing processes, and innovative AAV analytics have been integrated to generate a robust and scalable platform.
|
|
|
|
In this webinar, explore strategies to meet the quality and regulatory requirements of cell and gene therapies, and discover more about Lonza's New Product Introduction (NPI) process for cell and gene therapy manufacturing, including how to identify issues early on, reduce quality and compliance risks, and avoid delays and rework.
|
|
|
|
Dr. Behnam Ahmadian Baghbaderani, Global Head of Process Development for Cell & Gene Technologies, Lonza, introduces best practices required to de-risk the commercial manufacturing of cell and gene therapies. Learn the principles of commercialization readiness and how to address logical steps in process development.
|
|
|